β-Cell toxicity of ATP-sensitive K+ channel-blocking insulin secretagogues

Rustenbeck, 2001, Desensitization of insulin secretory response to imidazolines, tolbutamide and quinine. I. Secretory and morphological studies, Biochem. Pharmacol., 62, 1685, 10.1016/S0006-2952(01)00792-4 Mourtada, 2000, Effects of imidazoline binding site ligands on the growth and viability of clonal pancreatic β-cells, Naunyn-Schmiedeberg’s Arch. Pharmacol., 361, 146, 10.1007/s002109900158 Efanova, 1998, Glucose and tolbutamide induce apoptosis in pancreatic β-cells. A process dependent on intracellular Ca2+ concentration, J. Biol. Chem., 273, 33501, 10.1074/jbc.273.50.33501 Ashcroft, 1999, ATP-sensitive K+-channels and insulin secretion: their role in health and disease, Diabetologia, 42, 903, 10.1007/s001250051247 Jonas, 1992, Imidazoline antagonists of α2-adrenoceptors increase insulin release in vitro by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, Br. J. Pharmacol., 107, 8, 10.1111/j.1476-5381.1992.tb14456.x Morgan, 1999, Imidazoline receptors: targets for novel antihyperglycemic agents, Exp. Opin. Invest. Drugs, 8, 575, 10.1517/13543784.8.5.575 Chan, 1991, The α2-adrenoceptor antagonist efaroxan modulates KATP channels in insulin-secreting-cells, Eur. J. Pharmacol., 204, 41, 10.1016/0014-2999(91)90833-C Chan, 2001, Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan, Diabetes, 50, 340, 10.2337/diabetes.50.2.340 Rustenbeck, 2001, Desensitization of insulin secretory response to imidazolines, tolbutamide and quinine. II. Electrophysiological and fluorimetric studies, Biochem. Pharmacol., 62, 1695, 10.1016/S0006-2952(01)00793-6 Jörns, 1997, Ultrastructural changes in isolated incubated ob/ob mouse pancreatic islets induced by alloxan, various alloxan derivatives and ninhydrin, J. Endocrinol., 155, 283 Jancic, 1992, Islet cell metabolism is reflected by the MTT (tetrazolium) colorimetric assay, Diabetologia, 35, 482, 10.1007/BF02342448 Steinfelder, 2000, A fast and sensitive technique to study the kinetics and the concentration-dependencies of DNA fragmentation in drug-induced apoptosis, J. Pharmacol. Toxicol. Methods, 43, 79, 10.1016/S1056-8719(00)00088-5 Bossy-Wetzel, 1998, Mitochondrial cytochrome C release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization, EMBO J., 17, 37, 10.1093/emboj/17.1.37 Liu, 1997, DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis, Cell, 89, 175, 10.1016/S0092-8674(00)80197-X Ferri, 2000, Control of apoptotic DNA degradation, Nat. Cell Biol., 2, E63, 10.1038/35008692 Thornberry, 1998, Caspases: enemies within, Science, 281, 1312, 10.1126/science.281.5381.1312 Slee, 1999, Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner, J. Cell. Biol., 144, 281, 10.1083/jcb.144.2.281 Krautheim, 1999, Phosphatase inhibitors induce defective hormone secretion in insulin-secreting cells and entry into apoptosis, Exp. Clin. Endocrinol. Diabetes, 107, 29, 10.1055/s-0029-1212069 Krautheim, 2000, Hamster pancreatic beta cell lines with altered sensitivity towards apoptotic signalling by phosphatase inhibitors, Br. J. Pharmacol., 129, 687, 10.1038/sj.bjp.0703113 Kerr JFR, Harmon BV. Definition and incidence of apoptosis: a historical perspective of cell death. In: Tomei LD, Cope FO, editors. Apoptosis—the molecular basis of cell death. Cold Spring: Harbor Laboratory Press; 1991. p. 5–29. Zhivotovsky, 1999, Caspases: their intracellular localization and translocation during apoptosis, Cell Death Differ., 6, 644, 10.1038/sj.cdd.4400536 Zamzami, 1997, Mitochondrial implication in accidental and programmed cell death: apoptosis and necrosis, J. Bioenerg. Biomembr., 29, 185, 10.1023/A:1022694131572 Sheperd, 1996, Elevation of cytosolic calcium by imidazolines in mouse islets of Langerhans: implications for stimulus-response coupling of insulin release, Br. J. Pharmacol., 119, 911, 10.1111/j.1476-5381.1996.tb15759.x Rustenbeck, 1997, Imidazoline/guanidinium binding sites and their relation to inhibition of KATP channels in pancreatic β-cells, Naunyn-Schmiedeberg’s Arch. Pharmacol., 356, 410, 10.1007/PL00005070 Orrenius, 1989, Role of Ca2+ in toxic cell killing, Trends Pharmacol. Sci., 10, 281, 10.1016/0165-6147(89)90029-1 Harman, 1995, An evaluation of the role of calcium in cell injury, Annu. Rev. Pharmacol. Toxicol., 35, 129, 10.1146/annurev.pa.35.040195.001021 Zaitsev, 2001, Imidazoline compounds protect against interleukin 1β-induced β-cell apoptosis, Diabetes, 50, S70, 10.2337/diabetes.50.2007.S70 Gao, 2003, Effects of the imidazoline binding site ligands, idazoxan and efaroxan, on the viability of insulin-secreting BRIN-BD11 cells. JOP, J. Pancreas (Online), 4, 117 Tiedge, 1998, Complementary action of antioxidant enzymes in the protection of bioengineered insulin-producing RINm5F cells against the toxicity of reactive oxygen species, Diabetes, 47, 1578, 10.2337/diabetes.47.10.1578 Jörns, 1999, Effect of superoxide dismutase, catalase, chelating agents, and free radical scavengers on the toxicity of alloxan to isolated pancreatic islets in vitro, Free Radic. Biol. Med., 26, 1300, 10.1016/S0891-5849(98)00325-6